多替阿巴拉米片哪里生产的？

On January 22, 2018, British GlaxoSmithKline (GSK) announced that its controlling joint venture ViiV Healthcare will be used to treat HIV The single-pill compound preparation Triumeq (chemical name: Triumeq), which is based on the new generation of integrase inhibitor Triumeq (chemical name: dolutegravir), is officially launched in mainland China. This drug is the only three-in-one compound drug containing dolutegravir. It takes one tablet once a day and has the characteristics of high efficiency, good tolerance, high resistance barrier and few drug interactions.

Dolutegra abalamib tablets are indicated for use in adults and adolescents over 12 years old (weight at least 40 kg) infected with human immunodeficiency virus (HIV) (in HIV-infected patients, regardless of the patient's race, before starting treatment with abacavir-containing products, they should be screened for H LA-B*5701 allele. If the patient is known to carry the RLA-B*5701 allele, he should not take treatment with products containing abacavir. The treatment effect varies from person to person, and different physiques and medication methods will have an impact on the effectiveness of the drug.

are fixed-dose tablets and should not be used in patients requiring dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these circumstances, physicians should refer to the respective product information for these medicines. If the patient misses a dose of Suimei Kai and there are more than 4 hours before the next dose, Sui Meikai should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.